Toggle navigation
Menu
About Us
Investment Strategy
Team
Portfolio
News
Contact Us
Limited Partners
Portfolio
ZIOPHARM Oncology
Develops risk-sensitive in-licensed cancer drugs to address unmet medical needs
Boston, MA
NASDAQ: ZIOP
Contact:
Scott Barry
www.ziopharm.com
Related News
ZIOPHARM Receives Positive Opinion for Orphan Drug Designation for Darinaparsin from European Medicines Agency
ZIOPHARM Oncology and Intrexon Announce Worldwide Partnership for Synthetic Biology DNA-based Oncology Therapeutics
Ziopharm Adds $50M, Pushing Internal, Partnered Programs
ZIOPHARM and Solasia Pharma Announce License and Collaboration Agreement for Darinaparsin in Asia